CanSino Biologics (KG:6185, SHA:688185) said Malaysia's National Pharmaceutical Regulatory Agency has granted a Good Manufacturing Practice certificate under the Pharmaceutical Inspection Co-Operation Scheme for its vaccine manufacturing site, according to a Thursday Hong Kong bourse filing.
Hong Kong-listed shares of the firm were up nearly 1% in Friday morning trade.
The certification covers production of the Group ACYW135 meningococcal polysaccharide conjugate vaccine (MCV4) and the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13i).